Filing Flows › Cue Biopharma (CUE) › R&D spending
Cue Biopharma (CUE) R&D spending by quarter
Cue Biopharma's R&D spending was $49.0M in Q2 2026 (second quarter 2026), +611% from Q1 2026. Over the last 7 quarters it ranged from $4.8M (Q3 2025) to $49.0M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $49.0M | +611% | +520% |
| Q1 2026 | $6.9M | -58% | -19% |
| Q4 2025 | $16.5M | +248% | +130% |
| Q3 2025 | $4.8M | -40% | — |
| Q2 2025 | $7.9M | -7% | — |
| Q1 2025 | $8.5M | +19% | — |
| Q4 2024 | $7.2M | — | — |
Q2 2026 at a glance
Cue Biopharma, Q2 2026: revenue $7.9M (+167% year over year), net loss $153M, operating cash flow −$29.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Cue Biopharma's R&D spending?
Cue Biopharma's R&D spending was $49.0M in Q2 2026 (second quarter 2026), +611% from Q1 2026.
How has Cue Biopharma's R&D spending changed?
Over the last 7 quarters it ranged from $4.8M (Q3 2025) to $49.0M (Q2 2026).